CN104353058A - 商陆抗病毒蛋白冻干粉复合剂及其制备方法 - Google Patents
商陆抗病毒蛋白冻干粉复合剂及其制备方法 Download PDFInfo
- Publication number
- CN104353058A CN104353058A CN201410541305.3A CN201410541305A CN104353058A CN 104353058 A CN104353058 A CN 104353058A CN 201410541305 A CN201410541305 A CN 201410541305A CN 104353058 A CN104353058 A CN 104353058A
- Authority
- CN
- China
- Prior art keywords
- pokeweed antiviral
- antiviral protein
- lyophilized powder
- complexing agent
- hpv
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108700028325 pokeweed antiviral Proteins 0.000 title claims abstract description 176
- 239000000843 powder Substances 0.000 title claims abstract description 29
- 238000002360 preparation method Methods 0.000 title claims abstract description 23
- 239000003795 chemical substances by application Substances 0.000 title claims abstract description 9
- 238000013329 compounding Methods 0.000 title abstract 4
- 238000011282 treatment Methods 0.000 claims abstract description 48
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims abstract description 33
- 150000004676 glycans Chemical class 0.000 claims abstract description 19
- 229920001282 polysaccharide Polymers 0.000 claims abstract description 19
- 239000005017 polysaccharide Substances 0.000 claims abstract description 19
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 16
- 201000010099 disease Diseases 0.000 claims abstract description 15
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 15
- KQLDDLUWUFBQHP-UHFFFAOYSA-N Cordycepin Natural products C1=NC=2C(N)=NC=NC=2N1C1OCC(CO)C1O KQLDDLUWUFBQHP-UHFFFAOYSA-N 0.000 claims abstract description 14
- OFEZSBMBBKLLBJ-BAJZRUMYSA-N cordycepin Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)C[C@H]1O OFEZSBMBBKLLBJ-BAJZRUMYSA-N 0.000 claims abstract description 14
- OFEZSBMBBKLLBJ-UHFFFAOYSA-N cordycepine Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(CO)CC1O OFEZSBMBBKLLBJ-UHFFFAOYSA-N 0.000 claims abstract description 14
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 claims abstract description 12
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 claims abstract description 12
- 229940041616 menthol Drugs 0.000 claims abstract description 12
- 230000002265 prevention Effects 0.000 claims abstract description 12
- SUHOOTKUPISOBE-UHFFFAOYSA-N O-phosphoethanolamine Chemical compound NCCOP(O)(O)=O SUHOOTKUPISOBE-UHFFFAOYSA-N 0.000 claims abstract description 8
- 239000008176 lyophilized powder Substances 0.000 claims description 100
- 239000008139 complexing agent Substances 0.000 claims description 90
- 238000000034 method Methods 0.000 claims description 26
- 108090000623 proteins and genes Proteins 0.000 claims description 23
- 239000006166 lysate Substances 0.000 claims description 20
- 239000007787 solid Substances 0.000 claims description 20
- 239000000284 extract Substances 0.000 claims description 15
- 239000006228 supernatant Substances 0.000 claims description 15
- OWODMVTTWPVWQA-UHFFFAOYSA-N 10,11-dihydroxy-9-(hydroxymethyl)-2,6a,6b,9,12a-pentamethyl-1,3,4,5,6,6a,7,8,8a,10,11,12,13,14b-tetradecahydropicene-2,4a-dicarboxylic acid Chemical compound C12CC=C3C4CC(C)(C(O)=O)CCC4(C(O)=O)CCC3(C)C1(C)CCC1C2(C)CC(O)C(O)C1(CO)C OWODMVTTWPVWQA-UHFFFAOYSA-N 0.000 claims description 13
- 239000000203 mixture Substances 0.000 claims description 13
- 102000004169 proteins and genes Human genes 0.000 claims description 12
- 230000002421 anti-septic effect Effects 0.000 claims description 11
- 235000019750 Crude protein Nutrition 0.000 claims description 10
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 claims description 10
- 229910052921 ammonium sulfate Inorganic materials 0.000 claims description 10
- 235000011130 ammonium sulphate Nutrition 0.000 claims description 10
- 238000000746 purification Methods 0.000 claims description 10
- 230000008859 change Effects 0.000 claims description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 8
- 238000003756 stirring Methods 0.000 claims description 8
- 238000001291 vacuum drying Methods 0.000 claims description 8
- 238000005516 engineering process Methods 0.000 claims description 7
- 238000004108 freeze drying Methods 0.000 claims description 7
- 241000196324 Embryophyta Species 0.000 claims description 6
- -1 fluidizer Substances 0.000 claims description 6
- 238000005119 centrifugation Methods 0.000 claims description 5
- 238000002523 gelfiltration Methods 0.000 claims description 5
- 238000000227 grinding Methods 0.000 claims description 5
- 238000004255 ion exchange chromatography Methods 0.000 claims description 5
- 239000008363 phosphate buffer Substances 0.000 claims description 5
- 235000021110 pickles Nutrition 0.000 claims description 5
- 239000002244 precipitate Substances 0.000 claims description 5
- 239000002904 solvent Substances 0.000 claims description 5
- 239000002562 thickening agent Substances 0.000 claims description 5
- 241000219506 Phytolacca Species 0.000 claims description 4
- 241000190633 Cordyceps Species 0.000 claims description 3
- 229920001503 Glucan Polymers 0.000 claims description 3
- 229920000057 Mannan Polymers 0.000 claims description 3
- 240000008013 Phytolacca acinosa Species 0.000 claims description 3
- 235000009076 Phytolacca acinosa Nutrition 0.000 claims description 3
- TWNIBLMWSKIRAT-VFUOTHLCSA-N levoglucosan Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@H]2CO[C@@H]1O2 TWNIBLMWSKIRAT-VFUOTHLCSA-N 0.000 claims description 3
- 229910019142 PO4 Inorganic materials 0.000 claims description 2
- 240000007643 Phytolacca americana Species 0.000 claims description 2
- 235000009074 Phytolacca americana Nutrition 0.000 claims description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 2
- 239000010452 phosphate Substances 0.000 claims description 2
- 238000000605 extraction Methods 0.000 claims 2
- 241000701806 Human papillomavirus Species 0.000 abstract description 118
- 206010008342 Cervix carcinoma Diseases 0.000 abstract description 27
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 abstract description 27
- 201000010881 cervical cancer Diseases 0.000 abstract description 27
- 230000009385 viral infection Effects 0.000 abstract description 20
- 230000003628 erosive effect Effects 0.000 abstract description 19
- 208000009608 Papillomavirus Infections Diseases 0.000 abstract description 13
- 201000003505 cervical polyp Diseases 0.000 abstract description 13
- 206010020880 Hypertrophy Diseases 0.000 abstract description 4
- 206010008263 Cervical dysplasia Diseases 0.000 abstract 2
- 208000007951 cervical intraepithelial neoplasia Diseases 0.000 abstract 2
- 238000004090 dissolution Methods 0.000 abstract 2
- 239000007788 liquid Substances 0.000 abstract 2
- 208000002471 Penile Neoplasms Diseases 0.000 abstract 1
- 206010034299 Penile cancer Diseases 0.000 abstract 1
- 229930190792 Phytolaccasaponin Natural products 0.000 abstract 1
- 230000002888 effect on disease Effects 0.000 abstract 1
- 239000003755 preservative agent Substances 0.000 abstract 1
- 230000002335 preservative effect Effects 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 34
- 206010028980 Neoplasm Diseases 0.000 description 27
- 241000700605 Viruses Species 0.000 description 23
- 238000012360 testing method Methods 0.000 description 20
- 208000036142 Viral infection Diseases 0.000 description 19
- 208000015181 infectious disease Diseases 0.000 description 19
- 230000003612 virological effect Effects 0.000 description 16
- 210000003679 cervix uteri Anatomy 0.000 description 14
- 230000000694 effects Effects 0.000 description 14
- 108020004414 DNA Proteins 0.000 description 11
- 240000008042 Zea mays Species 0.000 description 11
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 11
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 11
- 235000005822 corn Nutrition 0.000 description 11
- 239000003814 drug Substances 0.000 description 11
- 230000014509 gene expression Effects 0.000 description 11
- 238000006243 chemical reaction Methods 0.000 description 10
- 206010059313 Anogenital warts Diseases 0.000 description 9
- 210000000981 epithelium Anatomy 0.000 description 8
- 241000341655 Human papillomavirus type 16 Species 0.000 description 7
- 108020005202 Viral DNA Proteins 0.000 description 7
- 210000004392 genitalia Anatomy 0.000 description 7
- 230000001225 therapeutic effect Effects 0.000 description 7
- 208000032420 Latent Infection Diseases 0.000 description 6
- 208000037771 disease arising from reactivation of latent virus Diseases 0.000 description 6
- 101150013359 E7 gene Proteins 0.000 description 5
- 210000000270 basal cell Anatomy 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 231100000915 pathological change Toxicity 0.000 description 5
- 230000036285 pathological change Effects 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 108091028043 Nucleic acid sequence Proteins 0.000 description 4
- 108700020796 Oncogene Proteins 0.000 description 4
- 208000037581 Persistent Infection Diseases 0.000 description 4
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 230000022131 cell cycle Effects 0.000 description 4
- 230000001413 cellular effect Effects 0.000 description 4
- 210000002919 epithelial cell Anatomy 0.000 description 4
- 238000011835 investigation Methods 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 230000001629 suppression Effects 0.000 description 4
- 230000001052 transient effect Effects 0.000 description 4
- 210000001215 vagina Anatomy 0.000 description 4
- 241000701022 Cytomegalovirus Species 0.000 description 3
- 101150071673 E6 gene Proteins 0.000 description 3
- 241000725303 Human immunodeficiency virus Species 0.000 description 3
- 206010027336 Menstruation delayed Diseases 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 108700026244 Open Reading Frames Proteins 0.000 description 3
- 241000700584 Simplexvirus Species 0.000 description 3
- 210000000234 capsid Anatomy 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 210000001163 endosome Anatomy 0.000 description 3
- 210000005002 female reproductive tract Anatomy 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 230000009826 neoplastic cell growth Effects 0.000 description 3
- 210000002445 nipple Anatomy 0.000 description 3
- 238000004806 packaging method and process Methods 0.000 description 3
- 238000001243 protein synthesis Methods 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 230000001568 sexual effect Effects 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- 230000014616 translation Effects 0.000 description 3
- 230000029812 viral genome replication Effects 0.000 description 3
- 210000002845 virion Anatomy 0.000 description 3
- GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 description 2
- 241000991587 Enterovirus C Species 0.000 description 2
- 102000014150 Interferons Human genes 0.000 description 2
- 108010050904 Interferons Proteins 0.000 description 2
- 101150075239 L1 gene Proteins 0.000 description 2
- 241000780272 Mammilla Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 241001631646 Papillomaviridae Species 0.000 description 2
- 108090000829 Ribosome Inactivating Proteins Proteins 0.000 description 2
- 206010046914 Vaginal infection Diseases 0.000 description 2
- 108020000999 Viral RNA Proteins 0.000 description 2
- 230000000840 anti-viral effect Effects 0.000 description 2
- 210000002469 basement membrane Anatomy 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 210000000349 chromosome Anatomy 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 230000008034 disappearance Effects 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 230000010354 integration Effects 0.000 description 2
- 229940079322 interferon Drugs 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 206010025482 malaise Diseases 0.000 description 2
- 230000002018 overexpression Effects 0.000 description 2
- 208000030940 penile carcinoma Diseases 0.000 description 2
- 201000008174 penis carcinoma Diseases 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 210000004999 sex organ Anatomy 0.000 description 2
- 238000012109 statistical procedure Methods 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 230000008957 viral persistence Effects 0.000 description 2
- 206010007134 Candida infections Diseases 0.000 description 1
- 108090000565 Capsid Proteins Proteins 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 102100023321 Ceruloplasmin Human genes 0.000 description 1
- 208000011359 Chromosome disease Diseases 0.000 description 1
- 206010062317 Condyloma latum Diseases 0.000 description 1
- 208000000907 Condylomata Acuminata Diseases 0.000 description 1
- 206010011409 Cross infection Diseases 0.000 description 1
- 206010067477 Cytogenetic abnormality Diseases 0.000 description 1
- 230000004543 DNA replication Effects 0.000 description 1
- 230000004568 DNA-binding Effects 0.000 description 1
- 101150000092 E5 gene Proteins 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 102000004961 Furin Human genes 0.000 description 1
- 108090001126 Furin Proteins 0.000 description 1
- 102000008055 Heparan Sulfate Proteoglycans Human genes 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 108010064548 Lymphocyte Function-Associated Antigen-1 Proteins 0.000 description 1
- 241000712899 Lymphocytic choriomeningitis mammarenavirus Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 101710135898 Myc proto-oncogene protein Proteins 0.000 description 1
- 102100038895 Myc proto-oncogene protein Human genes 0.000 description 1
- 206010029803 Nosocomial infection Diseases 0.000 description 1
- 102000043276 Oncogene Human genes 0.000 description 1
- 102000006437 Proprotein Convertases Human genes 0.000 description 1
- 108010044159 Proprotein Convertases Proteins 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 101000933967 Pseudomonas phage KPP25 Major capsid protein Proteins 0.000 description 1
- 238000010240 RT-PCR analysis Methods 0.000 description 1
- 241000272534 Struthio camelus Species 0.000 description 1
- 108090000054 Syndecan-2 Proteins 0.000 description 1
- 101710150448 Transcriptional regulator Myc Proteins 0.000 description 1
- 201000008100 Vaginitis Diseases 0.000 description 1
- 108700005077 Viral Genes Proteins 0.000 description 1
- 108010049024 Viral Oncogene Proteins Proteins 0.000 description 1
- 206010056530 Vulvovaginal pruritus Diseases 0.000 description 1
- 206010048038 Wound infection Diseases 0.000 description 1
- 206010000210 abortion Diseases 0.000 description 1
- 231100000176 abortion Toxicity 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000032677 cell aging Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 208000019065 cervical carcinoma Diseases 0.000 description 1
- 210000003756 cervix mucus Anatomy 0.000 description 1
- 208000024971 chromosomal disease Diseases 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 238000002573 colposcopy Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000009849 deactivation Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 229940059082 douche Drugs 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000012202 endocytosis Effects 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 210000004996 female reproductive system Anatomy 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 102000034287 fluorescent proteins Human genes 0.000 description 1
- 108091006047 fluorescent proteins Proteins 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 230000030279 gene silencing Effects 0.000 description 1
- 238000012226 gene silencing method Methods 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000002962 histologic effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 230000001861 immunosuppressant effect Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 239000000865 liniment Substances 0.000 description 1
- 229940040145 liniment Drugs 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 231100001134 median toxic concentration Toxicity 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 208000037819 metastatic cancer Diseases 0.000 description 1
- 208000011575 metastatic malignant neoplasm Diseases 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 231100000028 nontoxic concentration Toxicity 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 231100000590 oncogenic Toxicity 0.000 description 1
- 230000002246 oncogenic effect Effects 0.000 description 1
- 108091008819 oncoproteins Proteins 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 238000009595 pap smear Methods 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 208000015608 reproductive system cancer Diseases 0.000 description 1
- 208000017443 reproductive system disease Diseases 0.000 description 1
- 210000005000 reproductive tract Anatomy 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000007958 sleep Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 231100000588 tumorigenic Toxicity 0.000 description 1
- 230000000381 tumorigenic effect Effects 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 230000006648 viral gene expression Effects 0.000 description 1
- 230000009447 viral pathogenesis Effects 0.000 description 1
Abstract
Description
Claims (9)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410541305.3A CN104353058B (zh) | 2014-10-14 | 2014-10-14 | 商陆抗病毒蛋白冻干粉复合剂及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410541305.3A CN104353058B (zh) | 2014-10-14 | 2014-10-14 | 商陆抗病毒蛋白冻干粉复合剂及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN104353058A true CN104353058A (zh) | 2015-02-18 |
CN104353058B CN104353058B (zh) | 2016-12-07 |
Family
ID=52520431
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201410541305.3A Active CN104353058B (zh) | 2014-10-14 | 2014-10-14 | 商陆抗病毒蛋白冻干粉复合剂及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN104353058B (zh) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108514640A (zh) * | 2018-05-11 | 2018-09-11 | 江苏森瑞谱生物制药有限公司 | 含商陆抗病毒蛋白和免疫活性物质的药物组合物及其用途 |
CN109276703A (zh) * | 2018-11-06 | 2019-01-29 | 海南森瑞谱生命科学药业股份有限公司 | 植物抗病毒蛋白复合剂及其制备方法 |
CN109517042A (zh) * | 2018-11-02 | 2019-03-26 | 江苏正大天创生物工程有限公司 | 一种新型抗人乳头瘤病毒蛋白的制备方法 |
CN110016470A (zh) * | 2019-05-09 | 2019-07-16 | 江苏森瑞谱生物制药有限公司 | 一种从商陆中提取纯化商陆抗病毒蛋白的方法 |
CN110292621A (zh) * | 2019-07-16 | 2019-10-01 | 湖北亿彤实业有限公司 | 抗hpv病毒感染的抗毒抑菌复合剂及其转相凝胶的制备方法 |
CN114404565A (zh) * | 2018-04-23 | 2022-04-29 | 海南海泽惠生物科技有限公司 | β-苦瓜素在制备抗人乳头瘤病毒感染药物中的应用 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1279107A (zh) * | 1999-12-30 | 2001-01-10 | 辛耀禄 | 一种治疗艾滋病和肿瘤的药剂及其制备方法 |
CN101164583A (zh) * | 2006-10-16 | 2008-04-23 | 海南森瑞谱生命科学药业股份有限公司 | 治疗上皮糜烂的复合制剂及其制备方法 |
CN102008628A (zh) * | 2009-09-08 | 2011-04-13 | 深圳市隆阳生物科技有限公司 | 用于治疗女性生殖道病毒感染的药物及其缓释制剂的制备方法 |
US20140287990A1 (en) * | 2006-05-19 | 2014-09-25 | The Board Of Trustees Of The University Of Illinois | Compositions and methods to concurrently treat and/or prevent multiple diseases with cupredoxins |
-
2014
- 2014-10-14 CN CN201410541305.3A patent/CN104353058B/zh active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1279107A (zh) * | 1999-12-30 | 2001-01-10 | 辛耀禄 | 一种治疗艾滋病和肿瘤的药剂及其制备方法 |
US20140287990A1 (en) * | 2006-05-19 | 2014-09-25 | The Board Of Trustees Of The University Of Illinois | Compositions and methods to concurrently treat and/or prevent multiple diseases with cupredoxins |
CN101164583A (zh) * | 2006-10-16 | 2008-04-23 | 海南森瑞谱生命科学药业股份有限公司 | 治疗上皮糜烂的复合制剂及其制备方法 |
CN102008628A (zh) * | 2009-09-08 | 2011-04-13 | 深圳市隆阳生物科技有限公司 | 用于治疗女性生殖道病毒感染的药物及其缓释制剂的制备方法 |
Non-Patent Citations (1)
Title |
---|
JAMES D. IRVIN ET AL: "Pokeweed antiviral protein: Ribosome inactivation and therapeutic applications", 《PHARMACOLOGY & THERAPEUTICS》 * |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114404565A (zh) * | 2018-04-23 | 2022-04-29 | 海南海泽惠生物科技有限公司 | β-苦瓜素在制备抗人乳头瘤病毒感染药物中的应用 |
CN114404565B (zh) * | 2018-04-23 | 2023-09-26 | 海南海泽惠生物科技有限公司 | β-苦瓜素在制备抗人乳头瘤病毒感染药物中的应用 |
CN108514640A (zh) * | 2018-05-11 | 2018-09-11 | 江苏森瑞谱生物制药有限公司 | 含商陆抗病毒蛋白和免疫活性物质的药物组合物及其用途 |
CN109517042A (zh) * | 2018-11-02 | 2019-03-26 | 江苏正大天创生物工程有限公司 | 一种新型抗人乳头瘤病毒蛋白的制备方法 |
CN109276703A (zh) * | 2018-11-06 | 2019-01-29 | 海南森瑞谱生命科学药业股份有限公司 | 植物抗病毒蛋白复合剂及其制备方法 |
CN110016470A (zh) * | 2019-05-09 | 2019-07-16 | 江苏森瑞谱生物制药有限公司 | 一种从商陆中提取纯化商陆抗病毒蛋白的方法 |
CN110292621A (zh) * | 2019-07-16 | 2019-10-01 | 湖北亿彤实业有限公司 | 抗hpv病毒感染的抗毒抑菌复合剂及其转相凝胶的制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN104353058B (zh) | 2016-12-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104353058B (zh) | 商陆抗病毒蛋白冻干粉复合剂及其制备方法 | |
CN108606982B (zh) | Vcp抑制剂和溶瘤病毒在制备抗肿瘤药物中的应用 | |
CN103920081B (zh) | 一种药物组合物的用途 | |
CN105031625B (zh) | 一种电荷修饰的乳铁蛋白与卡拉胶组合药物及其制备方法 | |
JP6661800B2 (ja) | アルギン酸硫酸エステルおよびヒトパピローマウイルスによる疾患の予防および治療する薬物と健康食品の製造におけるその使用 | |
Bharti et al. | Therapeutic startegies for human papillomavirus infection and associated cancers | |
De Rosa et al. | Effect of immunomodulatory supplements based on Echinacea Angustifolia and Echinacea Purpurea on the posttreatment relapse incidence of genital condylomatosis: A prospective randomized study | |
CN106474147B (zh) | 一种预防和控制人乳头状瘤病毒感染的敷料及其制备方法 | |
RU2394586C2 (ru) | Применение скелета клеточной стенки nocardia rubra для получения лекарства против вируса папилломы человека (hpv) | |
CN113521156B (zh) | 一种中药组合物在制备抗宫颈癌前病变药物中的应用 | |
WO2013143412A1 (zh) | 药物组合物 | |
AU3702801A (en) | Pharmacological agent comprising picolinic acid, fusaric acid and derivatives thereof | |
Iljazović et al. | Efficacy in treatment of cervical HRHPV infection by combination of beta interferon, and herbal therapy in woman with different cervical lesions | |
CN108785656A (zh) | 一种降低宫颈癌发病风险的药物制剂及其制备方法 | |
Androphy | Papillomaviruses and interferon | |
US20040109899A1 (en) | Antiviral medicament and method for producing and using the same for the prophylactic and therapeutic treatment of papillomavirus induced tumors, lesions and deseases | |
CN108042524A (zh) | 丹酚酸b及其结构类似物在制备抗hpv病毒感染药物中的应用 | |
Lee et al. | Pine needle extract applicable to topical treatment for the prevention of human papillomavirus infection | |
CN110292621A (zh) | 抗hpv病毒感染的抗毒抑菌复合剂及其转相凝胶的制备方法 | |
CN106177900A (zh) | 一种抗人乳头瘤病毒的凝胶及其制备方法 | |
TW202023534A (zh) | 高風險人類乳突病毒感染的治療方法 | |
CN101711785A (zh) | 治疗人乳头瘤病毒感染的中药 | |
CN108042519A (zh) | 咖啡酸在制备抗hpv病毒感染药物中的应用 | |
CN113384548A (zh) | 一种具有抗hpv病毒感染的阴道泡腾片及其制备方法 | |
EP2952182B1 (en) | Compounds and methods for increasing the immune response to papillomavirus |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20191101 Address after: 225300 No. 6 Yuzhu Road, Taizhou Medical High-tech Zone, Jiangsu Province Patentee after: JIANGSU SR-BIOPHARMA BIOLOGICAL PHARMACEUTICAL CO.,LTD. Address before: The national high tech Industrial Park in Hainan province Haikou trough road 570000 No. 5 Patentee before: HAINAN SR-BIOPHARMA CO.,LTD. |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20210513 Address after: 570000 No.5, Yaogu 1st Road, national high tech Industrial Park, Haikou City, Hainan Province Patentee after: HAINAN SR-BIOPHARMA Co.,Ltd. Address before: 225300 No.6 Yuzhu Road, Taizhou pharmaceutical high tech Zone, Jiangsu Province Patentee before: JIANGSU SR-BIOPHARMA BIOLOGICAL PHARMACEUTICAL Co.,Ltd. |
|
CP03 | Change of name, title or address | ||
CP03 | Change of name, title or address |
Address after: No. 5 Yaogu 1st Road, National High tech Industrial Park, Haikou City, Hainan Province, 570311 Patentee after: Senruipu Life Science Pharmaceutical (Hainan) Group Co.,Ltd. Address before: 570000 No.5, Yaogu 1st Road, national high tech Industrial Park, Haikou City, Hainan Province Patentee before: HAINAN SR-BIOPHARMA CO.,LTD. |